Inspiratory Muscle Training in Sarcoidosis
Primary Purpose
Sarcoidosis
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Inspiratory muscle training
Sham inspiratory muscle training
Sponsored by
About this trial
This is an interventional supportive care trial for Sarcoidosis focused on measuring sarcoidosis, inspiratory muscle strength, exercise capacity, quality of life
Eligibility Criteria
Inclusion Criteria:
- Clinically stable
- Under standard medication
- Stage I and IV
- No change in medications over three months
Exclusion Criteria:
- Cognitive disorders
- Current corticosteroid use
- Having co-morbidity to prevent performing IMT
- Acute infection
- Orthopedic and neurological problems
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
Treatment group
Control group
Arm Description
Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
Sham: Control group received sham inspiratory muscle training using POWERbreathe Classic threshold loading device .
Outcomes
Primary Outcome Measures
Maximum inspiratory and expiratory muscle strength (MIP, MEP)
Mouth pressure device
Secondary Outcome Measures
Exercise Capacity
Six-minute walk test (6MWT)
Maximal Exercise Capacity
Modified incremental shuttle walk test (ISWT)
Fatigue
Fatigue Severity Scale (FSS)
Pulmonary function and diffusing capacity
Spirometry
Peripheral muscle strength
Hand-held dynamometer
Dyspnea
Modified Borg and Modified Medical Research Council (MMRC) dyspnea scales
Depression
Montgomery Asberg Depression Rating Scale (MADRS))
Quality of life
Saint George's Respiratory Questionnaire (SGRQ) (Turkish versions of all scales)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02270333
Brief Title
Inspiratory Muscle Training in Sarcoidosis
Official Title
Effects of Inspiratory Muscle Training in Patients With Sarcoidosis
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
April 2012 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
April 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Gazi University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Respiratory muscle weakness results with decreased exercise capacity, worse fatigue, dyspnea and quality of life in patients with sarcoidosis. However, no study investigated the effects of inspiratory muscle training (IMT), therefore effects of IMT on outcomes in patients with sarcoidosis were investigated.
Detailed Description
Patients were diagnosed with sarcoidosis according to the criteria of the latest American Thoracic Society (ATS)/European Respiratory Society (ERS)/World Association of Sarcoidosis and Other Granulomatous (WASOG) Disorders statement on sarcoidosis. Primary outcome measurement was respiratory muscle strength, secondary outcomes were, exercise capacity quality of life, fatigue and depression.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcoidosis
Keywords
sarcoidosis, inspiratory muscle strength, exercise capacity, quality of life
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment group
Arm Type
Active Comparator
Arm Description
Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
Arm Title
Control group
Arm Type
Sham Comparator
Arm Description
Sham: Control group received sham inspiratory muscle training using POWERbreathe Classic threshold loading device .
Intervention Type
Device
Intervention Name(s)
Inspiratory muscle training
Intervention Description
Treatment group received inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).
The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.
The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.
Intervention Type
Device
Intervention Name(s)
Sham inspiratory muscle training
Intervention Description
Control group received sham inspiratory muscle training (IMT) at fixed workload, 5% of MIP using threshold loading device (POWERbreathe Classic device IMT Technologies Ltd. Birmingham, England).
The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.
Primary Outcome Measure Information:
Title
Maximum inspiratory and expiratory muscle strength (MIP, MEP)
Description
Mouth pressure device
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Exercise Capacity
Description
Six-minute walk test (6MWT)
Time Frame
6 weeks
Title
Maximal Exercise Capacity
Description
Modified incremental shuttle walk test (ISWT)
Time Frame
6 weeks
Title
Fatigue
Description
Fatigue Severity Scale (FSS)
Time Frame
6 weeks
Title
Pulmonary function and diffusing capacity
Description
Spirometry
Time Frame
6 weeks
Title
Peripheral muscle strength
Description
Hand-held dynamometer
Time Frame
6 weeks
Title
Dyspnea
Description
Modified Borg and Modified Medical Research Council (MMRC) dyspnea scales
Time Frame
6 weeks
Title
Depression
Description
Montgomery Asberg Depression Rating Scale (MADRS))
Time Frame
6 weeks
Title
Quality of life
Description
Saint George's Respiratory Questionnaire (SGRQ) (Turkish versions of all scales)
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinically stable
Under standard medication
Stage I and IV
No change in medications over three months
Exclusion Criteria:
Cognitive disorders
Current corticosteroid use
Having co-morbidity to prevent performing IMT
Acute infection
Orthopedic and neurological problems
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Müşerrefe Nur Karadallı, MSc.
Organizational Affiliation
Gazi University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Burcu Camcıoğlu, MSc.
Organizational Affiliation
Gazi University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Meral Boşnak Güçlü, PhD
Organizational Affiliation
Gazi University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Nurdan Köktürk, MD
Organizational Affiliation
Gazi University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Haluk Türktaş, MD
Organizational Affiliation
Gazi University
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
15618580
Citation
Spruit MA, Thomeer MJ, Gosselink R, Troosters T, Kasran A, Debrock AJ, Demedts MG, Decramer M. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax. 2005 Jan;60(1):32-8. doi: 10.1136/thx.2004.022244.
Results Reference
result
PubMed Identifier
17099029
Citation
Kabitz HJ, Lang F, Walterspacher S, Sorichter S, Muller-Quernheim J, Windisch W. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest. 2006 Nov;130(5):1496-502. doi: 10.1378/chest.130.5.1496.
Results Reference
result
PubMed Identifier
11451823
Citation
Baydur A, Alsalek M, Louie SG, Sharma OP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest. 2001 Jul;120(1):102-8. doi: 10.1378/chest.120.1.102.
Results Reference
result
PubMed Identifier
9230229
Citation
Wirnsberger RM, Drent M, Hekelaar N, Breteler MH, Drent S, Wouters EF, Dekhuijzen PN. Relationship between respiratory muscle function and quality of life in sarcoidosis. Eur Respir J. 1997 Jul;10(7):1450-5. doi: 10.1183/09031936.97.10071450.
Results Reference
result
PubMed Identifier
26715771
Citation
Karadalli MN, Bosnak-Guclu M, Camcioglu B, Kokturk N, Turktas H. Effects of Inspiratory Muscle Training in Subjects With Sarcoidosis: A Randomized Controlled Clinical Trial. Respir Care. 2016 Apr;61(4):483-94. doi: 10.4187/respcare.04312. Epub 2015 Dec 29.
Results Reference
derived
Learn more about this trial
Inspiratory Muscle Training in Sarcoidosis
We'll reach out to this number within 24 hrs